Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
BOTULINUM TOXIN-HUMAN EPIDERMAL GROWTH FACTOR FUSION PROTEIN HAVING IMPROVED SKIN CELL PROLIFERATION AND ANTIOXIDANT EFFECT, AND COSMETIC COMPOSITION CONTAINING SAME AS EFFECTIVE INGREDIENT FOR SKIN REGENERATION AND WRINKLE IMPROVEMENT
Document Type and Number:
WIPO Patent Application WO/2017/213287
Kind Code:
A1
Abstract:
The present invention relates to a botulinum toxin-human epidermal growth factor fusion protein, composed of the amino acid sequence of SEQ ID NO: 2, having an improved skin cell proliferation and antioxidant effect, a gene coding for botulinum toxin-human epidermal growth factor fusion protein composed of the E. coli codon-optimized base sequence of SEQ ID NO: 1, a recombinant vector carrying the gene, a host cell transformed with the recombinant vector, a method for producing botulinum toxin-human epidermal growth factor fusion protein by transforming a host cell with the recombinant vector, and a cosmetic composition comprising a botulinum toxin-human epidermal growth factor fusion protein as an effective ingredient for improving skin wrinkles and maintaining dermal resilience. Exhibiting the effect of improving skin wrinkle improvement and skin regeneration, the cosmetic composition of the present invention can find useful applications in the functional cosmetic field or the plastic surgery field in the future.

Inventors:
LEE SUN KYO (KR)
RYU HAN BONG (KR)
LEE SEONG RAN (KR)
CHOI JONG NAM (KR)
CHOI TAE WON (KR)
KIM TAE HYUN (KR)
JEONG TAE HWA (KR)
KWON HYEONG IL (KR)
Application Number:
PCT/KR2016/007985
Publication Date:
December 14, 2017
Filing Date:
July 22, 2016
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
NEXGEN BIOTECHNOLOGIES INC (KR)
International Classes:
C07K14/33; A61K8/64; A61K38/18; A61K38/48; A61Q19/00; C07K14/485; C12N15/62
Foreign References:
KR20050027838A2005-03-21
KR20150144735A2015-12-28
KR20150056022A2015-05-22
Other References:
FAHRER ET AL.: "A Cell -permeable Fusion Protein Based on Clostridium Botulinum C2 Toxin for Delivery of p53 Tumorsuppressor into Cancer Cells", P]OS ONE, vol. 8, no. 9, pages e72455, XP055447370
YANG ET AL.: "Diphtheria Toxin-epidermal Growth Factor Fusion Protein DAB389EGF for the Treatment of Bladder Cancer", CLINICAL CANCER RESEARCH, vol. 19, no. 1, 2013, pages 148 - 157, XP055447358
CHANDRAMOHAN ET AL.: "Toxin-based Targeted Therapy for Malignant Brain Tumors", CLINICAL AND DEVELOPMENTAL IMMUNOLOGY, vol. 2012, 2012, pages 1 - 15, XP055447360
THAKUR ET AL.: "Targeted Tumor Therapy by Epidermal Growth Factor Appended Toxin and Purified Saponin: An Evaluation of Toxicity and Therapeutic Potential in Syngeneic Tumor Bearing Mice", MOLECULAR ONCOLOGY, vol. 7, 2013, pages 475 - 483, XP028543805
DATABASE GenBank [O] 8 February 2007 (2007-02-08), XP055454821, Database accession no. ABM73969.1
HANAHAN, D., J. MOL. BIOL., vol. 166, 1983, pages 557 - 580
Attorney, Agent or Firm:
CHOI, Kyu Whan (KR)
Download PDF: